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Executive Summary 
Introduction 
This report is the first update of the systematic review on “Leadless pacemak-
ers for right ventricle pacing” prepared in March 2016 and comprises all new 
information from published and unpublished documents. 
Health Problem 
In the scope of this assessment are cardiac arrhythmias in adults for which 
single-chamber ventricular pacing (VVI) is indicated. First and foremost, 
these are patients with atrial fibrillation who require a pacemaker due to slow 
ventricular response, but also patients with bradycardia due to atrioventricu-
lar block or sinus node disease might be considered if other pacing modes 
are not appropriate. 
The purpose of cardiac pacing is to provide an appropriate heart rate and 
heart response to re-establish effective circulation and more normal haemo-
dynamics that are compromised by a slow heart rate. Permanent pacemaker 
implantation is further considered to alleviate symptoms associated with a 
bradyarrhythmia (e.g. dizziness, light-headedness, syncope, fatigue, poor exer-
cise tolerance) or to prevent the possible worsening of the rhythm disturbance. 
Description of Technology 
Leadless cardiac pacemakers are self-contained intracardiac devices that are 
designed to have the same function as conventional cardiac pacemakers, but 
are miniaturized and can be implanted entirely inside the right ventricle of 
the heart. The expected benefit is the avoidance of complications associated 
with the placement of an external pulse generator in a surgical pocket in the 
chest and the transmission of impulses through transvenous leads required 
in conventional pacemakers. 
 
Methods 
We assessed whether leadless cardiac pacemakers in comparison to conven-
tional pacemakers in patients with indications for right ventricle pacing are 
as effective and safe concerning exercise capacity and cardiovascular morbidi-
ty and mortality, and more effective and safe concerning health-related qual-
ity of life and complications rate. Therefore a systematic literature search in 
five different bibliographic databases and three clinical trials registries was 
conducted. Furthermore, the manufacturers of the relevant devices were con-
tacted for additional published or unpublished study results. The study se-
lection, data extraction and assessing the methodological quality of the stud-
ies was performed by two review authors (TS, NP) independently from each 
other. 
Domain effectiveness 
The following efficacy-related outcomes were used as evidence to derive a 
recommendation: health-related quality of life (HRQoL), exercise capacity. 
update 2017 
indication:  
cardiac arrhythmias 
leadless pacemakers:  
miniaturized, entirely 
implantable cardiac 
pacemakers 
systematic search in 
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Domain safety 
The following safety-related outcomes were used as evidence to derive a rec-
ommendation: mortality, serious adverse device effects (SADE), adverse de-
vice effects (ADE) and serious adverse events (SAE). 
 
Results 
Available evidence 
For this update-report, still, no comparative studies assessing leadless cardi-
ac pacemakers versus conventional pacemakers were available. We identified 
12 new relevant documents on three ongoing prospective multi-centre single 
arm studies and four small single-centre case series. The total number of pa-
tients analysed for efficacy and safety endpoints respectively were 1391 and 
1581. Atrial fibrillation with AV block was the major indication for pacing in 
the included studies. In three studies patients with contraindications for con-
ventional pacemakers were included and analysed. Mean age of the study par-
ticipants ranged from 75 to 79 years, and co-morbidities were frequent. Six 
of the seven studies investigated the Micra™ TPS, only one new publication 
reported results on the Nanostim™ LCP. 
Clinical effectiveness 
None of the studies reported efficacy results associated with cardiac arrhyth-
mias or results for exercise capacity. For HRQoL, conference proceedings on 
3-months interim analyses of the Micra Transcatheter Pacing Study and the 
LEADLESS II study reported statistically significant improvements from 
baseline in EQ-5D and SF-36 scores. 
Safety 
Overall mortality was reported in five studies and ranged from no death in 
three case series to a 10.3% mortality rate in the 12 months analysis of a large 
prospective multi-centre single-arm trial. Overall, two patients died due to 
the implant procedure. There were 16 cardiac injuries, one device dislodge-
ment and one major infection reported in the included Micra™ TPS studies. 
For Nanostim™ LCP, no new safety results were available since the report 
2016. 
Upcoming evidence 
There are no randomised or non-randomised controlled trials currently 
planned or ongoing. Five ongoing single-arm studies are registered, where 
safety endpoints and pacing thresholds are defined as primary endpoints. 
 
Discussion 
Leadless pacemakers might have the potential for being a treatment option 
for patients with indication VVI pacing, especially for patients with contra-
indications for traditional transvenous pacemaker implantation. Major device 
or procedure related complications were rare, but only short term results are 
available so far. Long-term issues such as battery longevity and device retriev-
al after a prolonged implantation time are not yet resolved. Currently, the 
Micra™ TPS is the only clinical available device, since implantation of the 
Nanostim™ LCP was stopped in late 2016 due to battery malfunctions.  
safety: mortality and 
complication rate 
no comparative studies 
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controlled trials 
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Available evidence is still very limited. There are no controlled trials – ran-
domised or non-randomised – comparing leadless pacemaker systems to well 
established conventional single-chamber pacemakers. The overall number of 
patients analysed is rather small and long-term efficacy and safety results are 
missing.  
 
Conclusion 
Current evidence is still not sufficient to prove, that the assessed technology 
“Leadless pacemakers” is as effective but more safe than conventional VVI 
pacemakers. Therefore the inclusion of the technology in the catalogue of 
benefits is still not recommended. 
 
  
evidence limited: 
no direct comparison  
to conventional 
pacemakers;  
no long-term results 
evidence still  
not sufficient for 
recommendation 
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Zusammenfassung 
Einleitung 
Der vorliegende Bericht ist das erste Update des im März 2016 erstellten sys-
tematischen Reviews “Leadless pacemakers for right ventricle pacing“ und 
erfasst verfügbare neue Informationen aus publizierten und nicht-publizier-
ten Dokumenten zu diesem Thema. 
Indikation und therapeutisches Ziel 
Gegenstand der Untersuchung sind kardiale Arrhythmien, die eine Indika-
tion für einen Einkammerschrittmacher in der rechten Herzkammer (VVI-
Schrittmacher) darstellen. Dabei handelt es sich in erster Linie um PatientIn-
nen mit bradykardem, permanenten Vorhofflimmern, bei denen VVI-Schritt-
macher zur Überbrückung der bradykarden Phasen implantiert werden. Auch 
bei PatientInnen mit Bradykardien aufgrund eines Sick-Sinus-Syndroms oder 
atri-ventrikulärem Blocks kann ein VVI-Schrittmacher indiziert sein, wenn 
andere Schrittmachersysteme nicht in Frage kommen.  
Ziel der Schrittmachertherapie ist die Stabilisierung des Herzrhythmus und 
damit die Wiederherstellung eines effektiven Kreislaufs und normaler Hä-
modynamik, die durch die Bradykardie beeinträchtigt wurden. Damit sollen 
die Symptome, die mit Bradyarrhythmien einhergehen (z. B. Schwindel, Ohn-
macht, Müdigkeit, niedrige Belastungsfähigkeit) verringert werden. 
Beschreibung der Technologie 
Sondenlose Herzschrittmacher sind miniaturisierte, in sich geschlossene Herz-
schrittmacher, die dieselben Funktionen wie herkömmliche Herzschrittma-
cher erfüllen sollen, aber zur Gänze in die rechte Herzkammer implantiert 
werden können. Daraus erwartet man den Vorteil, dass Komplikationen im 
Zusammenhang mit dem externen Generator in einer subkutane Hauttasche 
und den transvenösen Sonden für die Impulsübertragung, die bei konventi-
onellen Herzschrittmachern notwendig sind, vermieden werden. 
 
Methoden 
Es wurde untersucht, ob sondenlose Herzschrittmacher im Vergleich zu kon-
ventionellen Herzschrittmachern in PatientInnen mit Indikationen für VVI-
Schrittmacher ebenso wirksam und sicher hinsichtlich der Endpunkte Belas-
tungsfähigkeit sowie kardialer Morbidität und Mortalität und wirksamer und 
sicherer hinsichtlich der Endpunkte gesundheitsbezogene Lebensqualität und 
Komplikationsrate sind. Dazu wurde eine systematische Literatursuche in 
fünf verschiedenen bibliografischen Datenbanken (Medline, PubMed, Em-
base, Cochrane library, CRD) sowie in drei Studienregistern durchgeführt. 
Zusätzlich wurden die Hersteller der Medizinprodukte im Hinblick auf wei-
tere publizierte und nicht publizierte Studienergebnisse kontaktiert Die Stu-
dienauswahl, Datenextraktion sowie die Bewertung der methodischen Quali-
tät der Studie wurde unabhängig voneinander von zwei ReviewerInnen (TS, 
NP) durchgeführt. Die Qualitätsbewertung der eingeschlossenen Studien er-
folgte nach den Methoden der EUnetHTA. Die Gesamtbeurteilung der Qua-
lität der Evidenz wurde mit der Grading Recommendations, Assessment, De-
velopment and Evaluation (GRADE)-Methode vorgenommen. 
Update 2017 
Indikation:  
kardiale Arrhythmien 
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Klinische Wirksamkeit 
Die folgenden Endpunkte wurden für die Bewertung der Wirksamkeit als 
entscheidend definiert: gesundheitsbezogene Lebensqualität, Belastungsfä-
higkeit. 
Sicherheit 
Die folgenden Endpunkte wurden für die Bewertung der Sicherheit als ent-
scheidend definiert: Mortalität, schwere produktbezogene unerwünschte Er-
eignisse (SADE), produktbezogene unerwünschte Ereignisse (ADE) sowie 
schwere unerwünschte Ereignisse (SAE). 
 
Ergebnisse 
Verfügbare Evidenz 
Es konnten keine kontrollierten Studien, randomisiert oder nicht-randomi-
siert, identifiziert werden, die sondenlose Herzschrittmacher im Vergleich zu 
konventionellen Herzschrittmachern untersuchten. Insgesamt konnten für 
das Update 12 neue relevante Dokumente zu drei laufenden prospektiven 
multizentrischen Einzelarmstudien sowie vier kleinen monozentrischen Fall-
serien eingeschlossen werden. Die Gesamtzahl der untersuchen PatientInnen 
betrug für die Wirksamkeitsparameter 1391 und für die Sicherheitsparame-
ter 1581 Personen. Die Hauptindikation für einen Herzschrittmacher in den 
Studien war Vorhofflimmern mit AV Block. In drei Studien wurden Patien-
tInnen mit Kontraindikationen für konventionelle Schrittmacher eingeschlos-
sen und ausgewertet. Das mittlere Alter der StudienteilnehmerInnen lag zwi-
schen 75 und 79 Jahren, bei der Mehrzahl lagen auch Begleiterkrankungen 
vor. In sechs der sieben eingeschlossenen Studien wurde das Micra™ TPS 
verwendet, nur eine neue Publikation berichtete Ergebnisse zum Nanostim™ 
LCP. 
Klinische Wirksamkeit 
Keine der Studien berichtete Ergebnisse zur Wirksamkeit im Hinblick auf 
kardiale Arrhythmien oder zur Belastungsfähigkeit. In zwei Konferenz-Abs-
tracts der Micra Transcatheter Pacing Study bzw. der LEADLESS II Studie 
wurden Ergebnisse zur gesundheitsbezogenen Lebensqualität nach 3 Mona-
ten Follow-up berichtet. Dabei zeigten sich statistisch signifikante Verbesse-
rungen in den EQ-5D und SF-36 Scores im Vergleich zu Studienbeginn.  
Sicherheit 
Aus fünf Studien lagen Ergebnisse zur Gesamtmortalität vor. Dabei wurde 
in drei Fall Serien berichtet, dass kein/e StudienteilnehmerIn in Zeitraum 
bis maximal 3 Monate nach Implantation verstarb. In zwei prospektiven mul-
tizentrischen Einzelarmstudien lag die Mortalitätsrate bei 2.8 % in 30 Tagen 
bzw. 10,3 % in 12 Monaten. Insgesamt wurden in den eingeschlossenen Stu-
dien zwei prozedur-bezogene Todesfälle berichtet. Darüber hinaus traten in 
den Studien 16 kardiale Verletzungen, eine Implantatsablösung sowie eine 
schwere Infektion in den Micra™ TPS Studien auf. Für den Nanostim™ LCP 
fanden sich keine neuen Ergebnisse zu Sicherheitsparametern seit dem Be-
richt 2016. 
Wirksamkeit: HRQoL 
und Belastungsfähigkeit 
Sicherheit: Mortalität, 
Komplikationsraten 
Keine Vergleichsstudien 
 
3 prospektive 
Einzelarmstudien und  
4 Fallserien 
HRQoL:  
Verbesserung nach 3 Mo 
Mortalität:  
10,3% nach 12 Mo 
 
16 P. mit kardialen 
Verletzungen 
 
1 Implantatsablösung,  
1 schwere Infektion 
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Laufende Studien 
Es finden sich derzeit keine Informationen hinsichtlich laufender oder ge-
planter randomisierter oder nicht-randomisierter kontrollierter Studie. In den 
Studienregistern sind fünf laufende Einzelarmstudien registriert, in denen 
Sicherheitsparameter und Reizschwellenwert als primäre Endpunkte definiert 
sind. 
 
Diskussion 
Sondenlose Herzschrittmacher könnten Behandlungsoption für PatientInnen 
mit Indikationen für VVI-Schrittmacher darstellen, im Besondern für Perso-
nen bei denen eine Kontraindikation für konventionelle Schrittmachern vor-
liegt. Schwere prozedur- oder produktbezogene Komplikationen treten in den 
vorliegenden Studien selten auf, jedoch handelt es sich dabei lediglich um 
Kurzzeitergebnisse. Langfristige Fragen im Hinblick auf die Lebensdauer der 
Batterien oder die Explantation nach langer Implantationsdauer sind derzeit 
noch offen. Batterie-Fehlfunktionen waren es auch, die Ende 2016 zu einem 
Stopp der Implantationen des Nanostim™ LCP führten, weshalb das Micra™ 
TPS das derzeit einzige verfügbare System am Markt ist. 
Insgesamt ist die derzeitige Evidenzlage immer noch sehr eingeschränkt. Es 
gibt keine Kontrollgruppenstudien, randomisiert oder nicht-randomisiert, die 
sondenlose Schrittmacher mit den etablierten konventionellen Schrittma-
chern vergleichen. Die Gesamtzahl der in den Studien untersuchten Patien-
tInnen ist verhältnismäßig klein und Langzeitergebnisse zur Wirksamkeit 
und Sicherheit fehlen. 
 
Empfehlung 
Die derzeitige Evidenz ist immer noch nicht ausreichend, um die untersuchte 
Technologie „Sondenlose Herzschrittmacher“ im Hinblick auf eine gleich-
wertige Wirksamkeit und eine erhöhte Sicherheit im Vergleich zu konventi-
onellen Schrittmachern beurteilen zu können. Daher wird eine Aufnahme in 
den Leistungskatalog weiterhin nicht empfohlen. 
 
derzeit keine laufenden 
kontrollierten Studien 
mögliche 
Behandlungsoption  
für bestimmte 
Personengruppen 
 
Langzeit-Fragen 
ungeklärt 
Evidenz sehr 
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VVI-Schrittmacher; 
keine Langzeitergebnisse 
Evidenz für  
Empfehlung weiterhin 
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Summary of the assessment 2016 
Commissioned by the Austrian Ministry of Health, the HTA-report “Leadless 
pacemakers for right ventricle pacing” was prepared by the Ludwig Boltz-
mann Institute of Health Technology Assessments (LBI-HTA) in March 2016 
[1]. This report provides the basis for the current update. The following par-
agraphs summarize the description of the health problem, the characteristics 
of technology, the results and the recommendation of the 2016 report.  
 
 
Health Problem and characteristics of the technology 
Pacemakers are developed for the treatment of a variety of cardiac arrhyth-
mias. Cardiac bradyarrhythmias are mainly due to either the incapacity of the 
sinus node to produce enough number of impulses per minute (sinus node 
disease) or the disturbance in atrioventricular (AV) conduction. In Austria, 
over 116,000 patients with cardiac arrhythmias were recorded in 2011 [2]. 
The natural history differs depending on the type of bradyarrhythmia. In pa-
tients with untreated AV block, death can occur due to heart failure second-
ary to low cardiac output or to sudden cardiac death caused by prolonged 
asystole or bradycardia-triggered ventricular tachyarrhythmia [3]. On the oth-
er hand, total survival and the risk of sudden cardiac death of patients with 
sinus node disease (SND, also sick sinus syndrome) are similar to the general 
population [4, 5]. Symptoms are present if bradycardia is severe enough to 
compromise blood flow: they may comprise fatigue, dizziness, syncope (faint-
ing), dyspnoea, chest pain, weakness and a reduced exercise capacity. 
Guidelines for implantation of permanent pacemakers have been established 
by the American College of Cardiology, the American Heart Association and 
the Heart Rhythm Society (ACC/AHA/HRS) [6] and by the European Socie-
ty of Cardiology (ESC) [3]. In patients with sinus node disease as well as in 
patients with atrial fibrillation, pacing is only indicated if bradycardia causes 
symptoms. Dual-chamber pacing is recommended over single-chamber ven-
tricular (VVI) pacing [3]. VVI pacing mode is the method of choice for pa-
tients with chronic atrial fibrillation (AF; ICD-10 I.44) who require a pace-
maker due to slow ventricular response [3]. This pacing mode may be con-
sidered for patients with AV block, even in the absence of AF, on an individu-
al basis, but in general is not considered the first choice [3]. 
Major complications associated with the implantation of a single-chamber 
right-ventricular pacemaker include lead-related re-interventions, local infec-
tions requiring re-intervention, device-related systemic infections, endocardi-
tis, pneumothorax requiring drainage, cardiac perforation, pocket revisions 
because of pain, generator-lead interface problems requiring re-intervention, 
haematomas requiring re-intervention, deep venous thrombosis, Twiddler’s 
syndrome, wound revisions, stroke, myocardial infarctions, and procedure-
related deaths [7, 8].  
Up to 6% of patients experience major complications within the first six 
months following implantation of cardiac electronic devices (all types), with 
lead-related re-intervention being the single most common complication. For 
single-chamber pacemakers, this risk is however significantly lower, with 3.3% 
systematischer Review 
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experiencing any major complication [8]. Especially the risk of lead compli-
cations is lower for single chamber right ventricular pacemakers compared 
to other pacemaker types [9].  
Leadless cardiac pacemakers (LCP) have been developed as alternatives for 
traditional permanent cardiac pacemakers. They are self-contained intracar-
diac devices that are designed to have the same function as traditional cardi-
ac pacemakers, but are miniaturized and can be implanted entirely inside the 
right ventricle of the heart via a steerable catheter [10]. The current genera-
tion of single-unit leadless cardiac pacemakers can only be used for single-
chamber pacing, specifically right ventricular pacing [11].  
At the time of the report 2016 two leadless pacing systems were available: the 
Nanostim™ LCP developed and manufactured by St. Jude Medical, which 
received CE market approval for Europe in 2013 but has not yet been ap-
proved for Australia and North America, and Medtronic´s Micra™ trans-
catheter pacing system (TPS), which was approved for the European market 
in 2015 and for the USA in 2016. Both devices are approximately ten times 
smaller than conventional VVI pacemakers and have an estimated battery 
longevity of approximately ten years, which is comparable to conventional 
pacemakers [10, 11] In contrast to traditional pacemakers, leadless pacemak-
ers do not require the placement of an external pulse generator in a surgical 
pocket in the chest and the transmission of impulses through transvenous 
leads. The claimed benefit is accordingly the avoidance of complications as-
sociated with these two components of traditional pacemaker implantation. 
 
 
Scope 
Are leadless pacemakers in comparison to conventional pacemakers in pa-
tients with indications for right ventricle pacing as effective and safe concern-
ing cardiovascular morbidity and mortality, exercise capacity, and more effec-
tive and safe concerning patient-related quality of life and complication rate?  
Inclusion criteria for relevant studies are summarised in Table 0-1. 
Table 0-1: Inclusion criteria 
Population First-line treatment of patients with indications for single-chamber ventricular pacemakers [3, 6] 
 Patients with chronic atrial fibrillation (AF; ICD-10 I.48) who require a pacemaker for 
persistent or intermittent bradycardia due to slow ventricular response (atrioventricular 
(AV) block, ICD-10 I.44) 
 Patients with persistent or intermittent bradycardia due to AV block or symptomatic 
sinus node disease (SND, ICD-10 I.49.5)1 
Contraindications:  
 Patients requiring long-term pacing exceeding estimated device longevity (NB. children) 
 Patients with indications for atrial single-chamber pacemakers or dual-chamber 
pacemakers or with indications for cardiac resynchronisation therapy  
MESH term: Arrhythmias, Cardiac [C14.280.067] and Arrhythmias, Cardiac [C23.550.073] 
 
                                                             
1 Only in specific instances, where other pacing modes (dual-pacing, atrial pacing) are 
not recommended  
LCP: miniaturisierte, 
vollständig 
implantierbare 
Herzschrittmacher  
Zwei Produkte: 
Nanostim™ LCP und 
Micra ™ TPS  
PIKO-Frage 2016 
Summary of the assessment 2016 
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Intervention Leadless self-contained and fully implantable VVI(R) pacemaker 
Setting: Vascular Surgery, Interventional Cardiology; specialist hospital, general hospital 
Products: Micra™ TPS, Medtronic Inc (available in Austria) 
Nanostim™, St. Jude Medical (available in Austria by end of 2016) 
MESH term: Pacemaker, Artificial [E07.305.250.750] 
Control Conventional VVI(R) pacemaker 
MESH term: Pacemaker, Artificial [E07.305.250.750] 
Outcomes  
Efficacy  Cardiovascular mortality 
 Cardiovascular morbidity  
 Patient-related quality of life 
 Exercise capacity 
 Pacing performance 
Safety Complication rate 
Study design  
Efficacy  Randomised controlled trials (Non-inferiority)2 
 Prospective non-randomised controlled trials 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective case series or registries with >100 patients 
ESC – European Society of Cardiology; AV – atrioventricular; TPS – transcatheter pacing system;  
VVIR – Single-chamber ventricular pacing with response modulation 
 
The following outcomes were defined as crucial to derive a recommendation 
in the report 2016. 
Clinical effectiveness: 
 Health-related quality of life (HRQoL)  
 Exercise capacity 
Safety: 
 Mortality (overall and procedure-related) 
 Complication rates  
 Serious Adverse Effect (SAE)  
 Adverse device effect (ADE)  
 Serious adverse device effect (SADE)  
 
 
                                                             
2 Randomised controlled trials comparing leadless pacemakers with traditional pace-
makers are desired, since they are appropriate (adequate number of patients, inter-
vention not urgent) and ethical (clinical equipoise, patients able to give consent) and 
necessary due to small plausible effect sizes. Blinding of operators and patients how-
ever is not possible, and placebo-controlled trials would be unethical due to the avail-
ability of an effective treatment. 
entscheidungsrelevante 
Endpunkte:  
Wirksamkeit – 
Lebensqualität,  
Belastungsfähigkeit  
Sicherheit – 
Komplikationsrate, 
Mortalität  
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Results 
No comparative studies to assess the effectiveness and safety of leadless pace-
makers could be identified. Five references on three prospective multi-centre 
single arm studies were included in the report 2016. Two studies investigated 
the Nanostim™ LCP and one study the Micra™ TPS. All of the studies were 
sponsored by the device manufacturers.  
Pacing performance was the primary efficacy endpoint in all of the included 
studies. However, none of the studies reported any of the clinical effective-
ness outcomes defined as crucial to derive a recommendation. 
Safety population of the three included studies comprises 1284 patients. Over-
all mortality was reported in all three studies and ranged from 3 to 5%. None 
of the death was classified as device related, but in total, four deaths in the 
three studies were related to the implantation procedure. Cardiac mortality 
was reported in two studies with 0.8% [12] and 1% [13, 14], respectively.  
The rates of SADE ranged between 4% and 6.5% in the three studies. Cardi-
ac injuries were reported in 20 patients, and device dislodgements in six pa-
tients, the latter all with the Nanostim™ LCP. Other SAE that were attribut-
able either to the device or the procedure included vascular complications, 
arrhythmia during device implantation and elevated pacing thresholds re-
quiring retrieval and implantation of a new device. 
The strength of evidence for the effectiveness and safety of leadless pacemak-
ers in comparison to conventional pacemakers was rated very low according 
to GRADE scheme. 
A search in clinical trial registries found no planned or ongoing randomised 
or non-randomised controlled trials on leadless pacemakers. A total of five 
ongoing single-arm studies, that will analyse safety endpoints and pacing 
thresholds, were identified 
 
 
Recommendation 
The evidence included in the report 2016 was not sufficient to prove, that the 
assessed technology Leadless Pacemakers is as effective but more safe than 
conventional VVI pacemakers. Therefore the inclusion of the technology in 
the catalogue of benefits was not recommended.  
 
keine Vergleichsstudien 
 
3 prospektive 
Einzelarmstudien 
keine Ergebnisse zu 
klinischer Wirksamkeit 
Sicherheit:  
3-5% Mortalität 
schwere 
produktbezogene 
Ereignisse:  
4-6.5% 
sehr niedrige 
Evidenzstärke 
Evidenz nicht 
ausreichend für 
Empfehlung 
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UPDATE 2017 
1 Scope 
1.1 PICO question 
Are leadless pacemakers in comparison to conventional pacemakers in patients 
with indications for right ventricle pacing as effective and safe concerning car-
diovascular morbidity and mortality, exercise capacity, and more effective and 
safe concerning patient-related quality of life and complication rate? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population First-line treatment of patients with indications for single-chamber ventricular pacemakers [3, 6] 
 Patients with chronic atrial fibrillation (AF; ICD-10 I.48) who require a pacemaker  
for persistent or intermittent bradycardia due to slow ventricular response 
(atrioventricular (AV) block, ICD-10 I.44) 
 Patients with persistent or intermittent bradycardia due to AV block or symptomatic 
sinus node disease (SND, ICD-10 I.49.5)3 
Contraindications:  
 Patients requiring long-term pacing exceeding estimated device longevity (NB. children) 
 Patients with indications for atrial single-chamber pacemakers or dual-chamber 
pacemakers or with indications for cardiac resynchronisation therapy  
MESH term: Arrhythmias, Cardiac [C14.280.067] and Arrhythmias, Cardiac [C23.550.073] 
Intervention Leadless self-contained and fully implantable VVI(R) pacemaker 
Setting: Vascular Surgery, Interventional Cardiology; specialist hospital, general hospital 
Products: Micra™ TPS, Medtronic Inc (available in Austria) 
Nanostim™, St. Jude Medical (available in Austria by end of 2016) 
MESH term: Pacemaker, Artificial [E07.305.250.750] 
Control Conventional VVI(R) pacemaker 
MESH term: Pacemaker, Artificial [E07.305.250.750] 
Outcomes  
Efficacy  Cardiovascular mortality 
 Cardiovascular morbidity  
 Patient-related quality of life 
 Exercise capacity 
 Pacing performance 
Safety Complication rate 
 
                                                             
3 Only in specific instances, where other pacing modes (dual-pacing, atrial pacing) are 
not recommended  
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Study design  
Efficacy  Randomised controlled trials (Non-inferiority)4 
 Prospective non-randomised controlled trials 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective case series or registries 
ESC – European Society of Cardiology; AV – atrioventricular; TPS – transcatheter pacing system;  
VVIR – Single-chamber ventricular pacing with response modulation 
 
 
 
                                                             
4 Randomised controlled trials comparing leadless pacemakers with traditional pace-
makers are desired, since they are appropriate (adequate number of patients, inter-
vention not urgent) and ethical (clinical equipoise, patients able to give consent) and 
necessary due to small plausible effect sizes. Blinding of operators and patients how-
ever is not possible, and placebo-controlled trials would be unethical due to the avail-
ability of an effective treatment. 
 LBI-HTA | 2017 17 
2 Methods 
2.1 Research questions 
Clinical Effectiveness 
Element ID Research question 
D0005 How do leadless pacemakers affect symptoms and findings (severity, frequency)  
of the disease or health condition? 
D0006 How do leadless pacemakers affect progression (or recurrence) of the disease  
or health condition? 
D0011 What is the effect of leadless pacemakers on patients’ body functions? 
D0012 What is the effect of leadless pacemakers on generic health-related quality of life? 
D0013 What is the effect of leadless pacemakers on disease-specific quality of life? 
D0016 How does the use of leadless pacemakers affect activities of daily living? 
D0017 Was the use of leadless pacemakers worthwhile? 
 
Safety 
Element ID Research question 
D0001 What is the expected beneficial effect of leadless pacemakers on mortality? 
D0003 What is the effect of leadless pacemakers on the mortality due to causes other  
than the target disease? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of the technology? 
C0007 Are leadless pacemakers and conventional single-chamber ventricular pacemakers 
associated with user-dependent harms? 
C0008 How safe are leadless pacemakers in comparison to conventional single-chamber  
ventricular pacemakers? 
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2.2 Systematic literature search 
The systematic literature search was conducted on the 06.04.2017  
in the following databases:  
 Medline via Ovid 
 PubMed 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
After deduplication, overall 168 citations were included. The specific search 
strategy employed can be found in the appendix. 
Manufacturers of the two available products (Medtronic, St. Jude Medical) 
were contacted and they submitted 20 documents of which 17 new citations 
were identified.  
Furthermore, a search in three clinical trials registries (ClinicalTrials.gov; 
WHO-ICTRP; EU Clinical Trials) was conducted on the 07.04.2017 result-
ing in 20 potential relevant hits. 
No additional references were found by hand search. 
 
  
systematische 
Literatursuche in  
5 Datenbanken 
insgesamt  
185 Publikationen 
identifiziert 
Methods 
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2.3 Flow chart of study selection 
Overall 185 hits were identified. The references were screened by two inde-
pendent researchers and in case of disagreement, a third researcher was in-
volved to solve the differences. From the search in bibliographic databases 
eight new articles [15-22], published since the previous report 2016 [1], were 
identified, that met the predefined inclusion criteria. A further four docu-
ments with additional information on relevant outcomes were identified from 
documents submitted by the manufacturers [23-26]. Altogether, a total of 12 
references [15-26] referring to seven studies were included in this update-re-
port. The selection process is displayed in Figure 2-1. 
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
Among the 20 potentially relevant hits in the clinical trials registries, we iden-
tified one additional unpublished completed study and five ongoing trials. 
For details see Table A-5. 
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 Additional records identified 
through other sources  
(n=17) 
Records after duplicates  
removed 
(n=185) 
Records screened 
(n=185) 
Records excluded 
(n=148) 
Full-text articles  
assessed for eligibility 
(n=37) Full-text articles excluded,  
with reasons 
(n=25) 
 Other study design (n=13) 
 Different outcome (n=10) 
 Not English/German (n=1) 
 Already included in previous 
report (n=1) 
Articles included in 
qualitative synthesis 
(n=12) 
 RCTs (n=0) 
 NRCTs (n=0) 
 Case-series  
(n=12 (7 studies)) 
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2.4 Analysis 
The information was retrieved from the sources identified.  
No further analysis was performed. 
Quality was assessed using the EUnetHTA checklist for case series [27]  
(see Table A-3). 
 
 
2.5 Synthesis 
The questions were answered in plain text format with reference to GRADE 
evidence tables [28] that are included in Table 5-1. 
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3 Clinical effectiveness 
3.1 Outcomes 
The implantation of pacemakers serves the primary purpose to alleviate symp-
toms associated with a slow heart rhythm. The pacemaker itself does not treat 
atrial fibrillation, the main indication for single chamber ventricular pacing. 
Recent reports indicate that prognosis of bradycardia pacemaker recipients 
are mainly determined by comorbitities and a bradycardia pacing indication 
as such does not influence survival [1]. 
The following outcomes were therefore defined as crucial to derive  
a recommendation: 
 Health-related quality of life (HRQoL) 
 Exercise capacity 
Pacing performance was the primary efficacy endpoint in all studies identi-
fied, however, this endpoint is not a clinical endpoint and hence was not de-
fined as crucial to derive a recommendation. 
 
 
3.2 Included studies 
There are still no comparative studies to assess the effectiveness of leadless 
pacemakers. For this update-report we identified eight relevant documents 
on three ongoing prospective multi-centre single arm studies that reported 
interim results on the performance of leadless pacemakers [16, 17, 21-26] and 
four additional references to four small single-centre case series [15, 18-20]. 
The total number of patients included in the efficacy analyses (pacing per-
formance) was 1,391. All three prospective multi-centre single arm studies 
were sponsored by device manufacturers, while the sponsor was not reported 
in the four case-series. In six of the included studies, the Medtronic Micra™ 
TPS was the investigated device [15-20, 22-26], while in one study the Nano-
stim™ LCP developed by St. Jude Medical was used [21]. 
In two conference proceedings of the Micra Transcatheter Pacing Study [23] 
and the LEASLESS II study [21] results on HRQoL including 956 partici-
pants were reported. These were the only available results on one of the effi-
cacy outcomes defined as crucial to derive a recommendation. 
All seven studies included patients with indications for VVI pacing. In addi-
tion, one case series included only patients contraindicated for or unable to 
receive conventional endovenous pacemaker implantation [19], while anoth-
er case series included only patients after lead extractions because of severe 
device infections [20]. The main indications for pacing were permanent, un-
controlled atrial fibrillation (range 21-70%), AV-block (range 10-100%) and 
sinus node dysfunction (range 8-17%). Mean age of the study participants was 
75 to 79 years. The study populations were predominantly male (range 50-83%).  
 
entscheidungsrelevante 
Endpunkte – Wirksamkeit: 
Lebensqualität, 
Beslastungsfähigkeit 
immer noch keine 
Vergleichsstudien 
 
seit Bericht 2016:  
neue Ergebnisse  
7 Studien;  
insgesamt  
1.391 PatientInnen  
2 Konferenz-Abstracts 
zu mit Ergebnissen zu 
HRQoL 
verschiedene 
Indikationen für  
VVI Schrittmacher 
 
2 Fallserien mit 
PatientInnen mit 
Kontraindikationen  
für konventionelle 
Schrittmacher 
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Comorbidities were frequent, with 57-86% of the participants suffering from 
hypertension. For one study [16, 22], subgroup efficacy results for patients 
with elevated implant threshold (i.e. (> 1.0 V at 0.24ms) were reported.  
Details on study characteristics and results of included studies are displayed 
in Table A-1 and Table A-2 and in the evidence profile in Table 5-1. 
 
 
3.3 Results 
Morbidity 
D0005 – How do leadless pacemakers affect symptoms and findings 
(severity, frequency) of cardiac arrhythmias? 
None of the studies reported results on symptoms associated with cardiac  
arrhythmias. 
D0006 – How do leadless pacemakers affect progression (or recurrence) 
of cardiac arrhythmias? 
None of the studies reported results on progression of cardiac arrhythmias.  
None of the studies reported pacing-induced arrhythmias. 
 
Function 
D0011 – What is the effect of leadless pacemakers  
on patients’ body functions? 
None of the studies reported results on patient’s body functions.  
D0016 – How does the use of leadless pacemakers affect activities  
of daily living? 
None of the studies reported results on exercise capacity. 
 
Health-related quality of life 
D0012 – What is the effect of leadless pacemakers  
on generic health-related quality of life?  
HRQoL was reported in conference proceedings of the LEADLESS II study 
[21] and the Micra Transcatheter Pacing Study [23], respectively. In the 
LEASLESS II study [21] 468 patients completed the EuroQol EQ-5D ques-
tionnaire at pre-discharge, and at weeks 2, 6 and 12. EQ-5D is a standard-
ized instrument for measuring generic health status. EQ-5D utility scales were 
calculated using the EuroQol US algorithm and ranged from 0.0 to 1.0. At pre-
discharge the mean EQ-5D utility score was 0.81. This score increased to 0.84 
in week 12. Compared to a baseline utility score of 0.73, which was obtained 
from a meta-analysis of single-chamber pacemaker studies in the US, the 
EQ-5D utility score increased by 14.7% (p<0.001). In the Micra Transcatheter 
Pacing Study [23], HRQoL was measured at baseline before implantation and 
at 3 months follow-up, using the SF-36 generic instrument. 488 patients were 
analysed. The results showed a significant improvement of the HRQoL scores 
in each of the eight SF-36 domains. At baseline, the mean composed physical 
hohes Alter, zahlreiche 
Begleiterkrankungen 
keine Ergebnisse zur 
Wirksamkeit in Bezug 
auf Arrhythmien 
keine Ergebnisse zur 
Belastungsfähigkeit 
Ergebnisse zur HRQoL 
aus 2 Studien: 
Bessere EQ-5D und  
SF-36 Scores nach  
3 Monaten 
Clinical effectiveness 
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summary score was 36.9 points and improved 3 months post-implant to 38.7 
points. In the same period, the mean mental component summary score im-
proved from 47.8 to 51.4 points. Both differences were statistically significant. 
D0013 – What is the effect of leadless pacemakers on disease-specific 
quality of life? 
None of the studies reported results on disease-specific quality of life. 
 
Patient satisfaction 
D0017 – Was the use of leadless pacemakers worthwhile?  
In the HRQoL publication of the Micra Transcatheter Pacing Study [23] some 
results on patient satisfaction were reported. After 3 months of follow-up 90%, 
96%, and 72% of patients were very satisfied or satisfied with their recovery, 
their aesthetic appearance, and their level of activity respectively, while 4% 
of the patients were dissatisfied with their recovery and 5% dissatisfied with 
their level of activity. 
 
keine Ergebnisse zur 
krankheitsspezifischen 
QoL 
Patientenzufriedenheit: 
Ergebnisse aus 1 Studie  
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4 Safety 
4.1 Outcomes 
The claimed benefit of leadless pacemakers in comparison to conventional 
pacemakers is the avoidance of complications associated with the surgical gen-
erator pocket or with the leads. In particular local complications such as hae-
matoma, skin breakdown or pocket infection, as well as lead failures and ve-
nous obstruction due to long term transvenous implantation can be ruled out 
using leadless pacemakers.  
However, complications related to the transvenous implantation procedure 
(cardiac tamponade, pneumothorax, device dislodgement) are a safety con-
cern with leadless pacemakers. The implantation of leadless pacemakers us-
es a different approach than that used for transvenous leads and requires sub-
stantially larger venous access tools. There were two halts to the Nanostim™ 
LCP trials in 2014 and 2015, due to reports of serious adverse events, includ-
ing perforation of the heart and dislodgement of the device [29]. 
Therefore, the following outcomes were defined as crucial to derive  
a recommendation: 
 Complication rates  
 Serious Adverse Effect (SAE) 
 Adverse device effect (ADE) 
 Serious adverse device effect (SADE) 
 Mortality (Overall and procedure-related) 
In accordance with the EC guidelines on serious adverse event reporting of 
medical devices5 these outcomes are defined as follows:  
Serious Adverse Event (SAE) is an adverse event that led to a death, to a seri-
ous deterioration in health of the subject, that either resulted in a life-threat-
ening illness or injury, or a permanent impairment of a body structure or a 
body function, or in-patient hospitalization or prolongation of existing hos-
pitalization, or in medical or surgical intervention to prevent life-threatening 
illness or injury or permanent impairment to a body structure or a body func-
tion. This includes device deficiencies that might have led to a serious adverse 
event if a) suitable action had not been taken or b) intervention had not been 
made or c) if circumstances had been less fortunate. 
Adverse Device Effect (ADE) is an adverse event related to the use of an inves-
tigational medical device. First, this includes any adverse event resulting from 
insufficiencies or inadequacies in the instructions for use, the deployment, the 
implantation, the installation, the operation, or any malfunction of the inves-
tigational medical device. Second, this includes any event that is a result of a 
use error or intentional abnormal use of the investigational medical device. 
Serious Adverse Device Effect (SADE) is an adverse device effect that has re-
sulted in any of the consequences characteristic of a serious adverse event. 
 
                                                             
5 http://ec.europa.eu/consumers/sectors/medical-
devices/files/meddev/2_7_3_en.pdf 
entscheidungsrelevante 
Endpunkte – Sicherheit: 
Komplikationsrate, 
Mortalität  
Leadless pacemakers for right ventricle pacing 
26 LBI-HTA | 2017 
4.2 Included Studies 
As for the efficacy results, there were no comparative studies assessing the 
safety of leadless pacemakers. For this update-report we identified eight rel-
evant documents on three ongoing prospective multi-centre single arm stud-
ies that reported interim results on the performance of leadless pacemakers 
[16, 17, 21-26] and four additional references to four small single-centre case 
series [15, 18-20] (see section 3.2). The total number of patients included in 
the safety analyses was 1,581. Details on study characteristics and results of 
included studies are displayed in Table A-1 and Table A-2 and in the evidence 
profile in Table 5-1. 
 
 
4.3 Results 
Mortality 
D0001 – What is the expected beneficial effect of leadless pacemakers on 
mortality? Patient safety 
Leadless pacemakers are not expected to have a beneficial effect on mortality 
compared to conventional VVI pacemakers.  
Overall mortality was reported in five of the included trials [15-17, 19, 20, 22-
26]. The 12 months interim analysis of the Micra Transcatheter Pacing Study 
[17] showed an overall mortality rate of 10.3% (77 of 745 patients), 32 of these 
were due to cardiac death. In the Micra Transcatheter Pacing System Post-Ap-
proval Registry [24-26] 22 of 795 patients died through 30 days post-implant 
(2.8%). In the three case series that reported on overall mortality, including 
14 [19], 10 [15] and 6 patients [20], none of the patients died during follow-
up. For the LEADLESS II study no new information on mortality was found 
in the included publication [21]. Safety results for this study can be found in 
the report 2016 [1].  
D0003 – What is the effect of leadless pacemakers  
on the mortality due to causes other than cardiac arrhythmia? 
Information on procedure-related mortality was found in five studies. While 
no procedure-related death was reported in the three case series [15, 19, 20], 
one patient died due to the implant procedure in the Micra Transcatheter Pac-
ing Study [17] and one in the Micra Transcatheter Pacing System Post-Ap-
proval Registry [25], respectively. None of these deaths were classified as re-
lated to the device. In the Micra Transcatheter Pacing study [17], a 77 year 
old female patient with end-stage renal disease died from metabolic acidosis 
due to a prolonged procedure time. In Micra Transcatheter Pacing System 
Post-Approval Registry [25], a 96 year old male patient with aortic valvular 
disease developed pulmonary edema one day after implant and was unable 
to be resuscitated. For the LEADLESS II study, no new information on pro-
cedural mortality was found in the included publication [21]. Safety results 
for this study can be found in the report 2016 [1].  
 
seit Bericht 2016:  
neue Ergebnisse  
7 Studien; insgesamt 
1.581 PatientInnen  
Gesamtmortalität –  
Prospektive 
Einzelarmstudie:  
10,3 % in 12 Monaten 
 
Fallserien:  
keine Todesfälle 
2 Todesfälle im 
Zusammenhang  
mit dem Eingriff 
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Patient safety  
C0008 – How safe are leadless pacemakers in comparison  
to conventional single-chamber ventricular pacemakers? 
SAE were only reported in the Micra Transcatheter Pacing Study [16, 17, 22, 
23], with 226 of 725 patients with events (31.2%) at 6 months follow-up. The 
number of overall adverse events was not reported in any of the included 
studies. 
SADE were reported in three studies. While in a case series [15] no major 
complication occurred during 55 days of follow-up, the rates in the two pro-
spective single-arm Micra studies ranged from 1.5% (12 of 795 patients; 30 
days follow-up) [25] to 4.0% (29/726 patients; 12 months) [17]. There were 
11 patients with cardiac injuries in the Micra Transcatheter Pacing Study [17] 
and five patients in the Micra Transcatheter Pacing System Post-Approval 
Registry [25]. Major device or procedure related cardiac events were report-
ed in three studies [16-19, 22, 23]. Six patients with cardiac failure, two with 
pacemaker syndrome and one patient with acute myocardial infarction with-
in 12 months of follow up in the Micra Transcatheter Pacing cohort [17], one 
patient with cardio-circulatory arrest related to a ventricular fibrillation one 
day after implantation in the case series of Da Costa 2017 [19] and one pa-
tient with moderate pericardial effusion in the case series of Martinez-Sande 
2017 [18]. One case of device dislodgement and one major infection were re-
ported within the six studies using the Micra TM TPS. Other SAE hat were 
attributable either to the device or the procedure included elevated pacing 
thresholds requiring retrieval and implantation of a new device, loss of de-
vice function, events at groin puncture site and embolism or thrombosis. For 
the LEADLESS II study, no new information on SADE was found in the in-
cluded publication [21]. Safety results for this study can be found in the re-
port 2016 [1]. 
C0005 – What are the susceptible patient groups  
that are more likely to be harmed through the use of the technology? 
There are not enough data to answer this question. 
C0007 – Are leadless pacemakers and conventional single-chamber 
ventricular pacemakers associated with user-dependent harms? 
Leadless pacemakers and conventional single-chamber ventricular pacemak-
ers are associated with user-dependent harms due to the risk of SAE related 
to the implantation procedure. 
 
SAE:  
31,2 % nach 6 Monaten 
SADE: 1,5-4 % 
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kardialen Verletzungen 
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Schäden bei beiden 
Interventionen möglich  
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5 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) scheme [28] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement, a third researcher was involved to solve the differ-
ence. A more detailed list of criteria applied can be found in the recommen-
dations of the GRADE Working Group [28].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in Table 5-1.  
Overall the strength of evidence for the effectiveness and safety of leadless 
pacemakers in comparison to conventional pacemakers is very low. 
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Table 5-1: Evidence profile: efficacy and safety of Leadless pacemakers 
No of 
studies/patients Study Design Estimate of effect 
Study 
limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength of 
evidence 
Efficacy 
Health related quality of life 
2/956 2 prospective single arm 
studies 
+5% improvement in SF-36 physical 
health score after 3 months 
+8% improvent in SF-36 mental helath 
score afer 3 months 
+15% improvement in EQ-5D utility 
score after 3 months 
-16 0 0 0 Very low 
Exercise capacity 
No data 
Safety 
Overall mortality 
5/1570 2 prospective single arm 
studies; 3 case series 
Range: 0-10.3% -16 0 0 -17 Very low 
Cardiovascular mortality 
4/775 1 prospective single arm 
study; 3 case series 
Range: 0-4.3% -16 0 0 -17 Very low 
Procedure-related mortality 
5/1570 2 prospective single arm 
studies; 3 case series 
Range: 0-0.1% -16 0 0 -17 Very low 
Major complication rate (SADE) 
3/1531 2 prospective single arm 
studies; 1 case series 
Range: 0-4,0% -16 0 0 -17 Very low 
Nomenclature for GRADE table:  
Limitations: 0: no limitations or no serious limitations; -1: serious limitations  
Inconsistency: NA: Not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty, -1: some uncertainty, -2 major uncertainty  
Other modifying factors: publication bias likely (-1), imprecise data (-1), strong or very strong association (+1 or +2), dose-response gradient (+1), Plausible confounding (+1)  
                                                             
6 No control group 
7 Imprecise data due to low number of events 
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6 Discussion 
This update report comprises new information from interim analyses of three 
large ongoing prospective multi-centre single-arm studies [16, 17, 21-26] and 
publications of four small single-centre case series [15, 18-20] on LCP, avail-
able since the previous report published in March 2016 [1]. As in the report 
2016, again no randomised or non-randomised controlled trials comparing 
leadless pacemaker systems to traditional single-chamber pacemakers could 
be identified. There are still no data on the effect of leadless cardiac pacemak-
ers on symptoms or progression of cardiac arrhythmias available. As in pre-
vious publications, the new evidence focusses on the feasibility and safety of 
the leadless pacemaker implantation procedure. Short-term results on HRQoL 
were only reported in two conference abstracts [21, 23]. 
The majority of the included studies (six of seven) in this update report as-
sessed the implantation of the Micra™ TPS [15-20, 22-26], while only one new 
publication was available for the Nanostim™ LCP [21]. Therefore the results 
of this update mainly refer to the Micra™ TCP, which is currently the only 
device which is available on the market. For the Nanostim™ LCP, all further 
implantations were stopped by the manufacturer in late 2016 and recruitment 
for all ongoing trials has been suspended. Reasons for this stop were reports 
of lost telemetry and pacing due to battery malfunctions in seven patients [30].  
Current results indicate that leadless pacemaker can be successfully implant-
ed in most of the patients – implantation rates ranged from 99.2 to 100% – 
and sustain a low pacing threshold (<1.0 V at 0.24ms) for up to 24 months. 
This low pacing threshold can also be achieved in patients with an elevated 
implant threshold [16, 22]. Interim results from the Micra Transcatheter 
Pacing Study [23] and the LEADLESS II study [21] showed an increase in 
HRQoL in the first 3 months after implantation. These results are not unex-
pected, since also studies on traditional pacemakers showed an increase in 
HRQoL in the first year after pacemaker implantation [31]. Thus, without 
comparative trials, it remains unclear whether the avoidance of lead/generator 
complications translates into a relevant HRQoL benefit for the patients or not. 
Major complication rates associated with the implantation procedure or the 
device were rare in the studies (0-4.0%) and might even be improved by a 
learning curve and/or special training to develop proficiency specific for the 
leadless pacemaker implantation [32]. Only one case of device dislodgement 
was reported within the included studies for the Micra™ TPS. Long term 
safety data were now available from one study with a follow-up of 12 months 
[17]. Within this period, 77 of 745 patients died, 32 due to cardiac reasons. 
Systemic infections occurred in 26 patients, all of them unrelated to the de-
vice or procedure and none of them classified as major infections. But again, 
since no direct comparisons to contemporary single-chamber systems exist, no 
definitive conclusion can be drawn on the superiority or even non-inferiority 
of the new technology compared to standard therapy. An indirect comparison 
with historical data from previous pacemaker studies, which was provided in 
the Micra Transcatheter Pacing Study [17], resulted in a 48% lower rate of 
patients with major complications. Buts these results are of limited validity, 
since the historic control included patients with dual-chamber pacemakers, 
for which higher complications rates have to be considered [7-9]. In a most 
recently published review results from an indirect comparison between lead-
less and traditional single-chamber pacemakers were reported [32]. In this 
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analysis, the short-term complication rate (≤ 2 months) of conventional pace-
makers (4.0%) appeared to be slightly lower compared to the leadless pace-
makers (4.8%). For long-term outcomes, no comparison was drawn, since for 
leadless pacemakers not enough data were available. 
Leadless pacemakers might represent a treatment alternative in patients, for 
whom an implantation of a transvenous pacemaker system is precluded. This 
includes patients with a compromised venous access, with a history of device 
infection or patients with cancer. Three of the included studies reported re-
sults on those patient groups. A subgroup analysis of the Micra Transcathe-
ter Pacing System Post-Approval Registry [26] analysing 104 patients with 
previously implanted cardiac implantable electronic devices, a case series with 
14 patients with full or relative contraindications for traditional transvenous 
pacemaker implantation [19] and another case series with six patients with 
lead extraction after severe device infections [20]. In all studies there was a 
100% successful implantation rate and the rates of major complication were 
very low. No device dislodgements or device infections occurred. Neverthe-
less, the number of patients investigated so far is very small and maximum 
follow-up was only 3 months. Therefore it remains unclear whether these pa-
tient groups are at increased risk for long-term complications, especially late 
infections or not. 
One issue concerning pacemakers is battery longevity. Based on the 6 months 
follow-up data it was estimated at 15.0 years for the Nanostim™ LCP and 
12.5 years for the Micra™ TPS [32]. However, these estimations are based on 
short-term data and might be overestimated [33], in particular, since discrep-
ancies between estimations and actual battery longevity were shown in stud-
ies on traditional pacemakers [33, 34]. In addition, as mentioned above, bat-
tery malfunctions already occurred in the Nanostim™ LCP. For the Micra™ 
TPS there is no evidence of similar battery issues [32].  
Another important feature, especially for leadless pacemakers, is their retriev-
ability. For the Nanostim™ LCP a steerable retrieval catheter was developed, 
while for the Micra™ TPS no such system is available [32]. However, the 
Micra™ TPS is not intended to be removed at the end of battery life [35]. In-
stead, the turned-off leadless pacemaker is abandoned in the right ventricle 
and another device is added. So far, there is no experience from human stud-
ies on the feasibility of the implantation of additional leadless pacemakers in 
the heart chamber. There is one publication on retrieval attempts after short- 
and mid-term implant time from three Nanostim™ LCP studies reporting 
successful retrieval in 15 of 16 patients with no related serious adverse events 
[36]. Retrievability of the leadless pacemaker after a prolonged implantation 
time has not been studied. 
In summary, the results from uncontrolled prospective multicentre trials and 
small case series indicate, that leadless pacemakers might have the potential 
for being a treatment option for patients with indication VVI pacing, especial-
ly for patients with contraindications for traditional transvenous pacemaker 
implantation. Nevertheless, the evidence is still limited. First of all, there are 
no controlled trials – randomised or non-randomised – comparing leadless 
pacemaker systems to well established traditional single-chamber pacemak-
ers. Second, relevant efficacy results (i.e. HRQoL) were only reported in con-
ference proceedings, no full peer-reviewed journal publications on that out-
come are currently available. Third, since the event rates in the relevant out-
comes were rather small, the number of patients analysed so far is too small 
to reach the optimal information size and therefore the results are imprecise.  
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And fourth, no long-term data on the performance of the leadless systems or 
on safety are yet available. So, as already mentioned in the 2016 report [1], 
further evaluation of leadless pacemakers for long-term clinical efficacy and 
complication rates, especially from controlled trials comparing them to tra-
ditional pacemakers is required. If long-term efficacy and safety can be 
demonstrated, leadless pacemakers may represent an alternative treatment 
option for a subset of patients with cardiac arrhythmias. 
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7 Recommendation 
In Table 7-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 7-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
x The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove, that the assessed technology 
“Leadless Pacemakers” is as effective but more safe than conventional VVI 
pacemakers. This conclusion is mainly based on the fact, that still no con-
trolled studies assessing leadless pacemakers in comparison to conventional 
pacemakers, the current well established standard interventions for the treat-
ment of a variety of cardiac arrhythmias, are available. New study results will 
potentially influence the effect estimate considerably. 
 
nach wie vor Evidenz 
nicht ausreichend für 
Empfehlung 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A-1: Leadless pacemakers: Results from observational studies (part 1) 
Study (acronym, ID no.) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
The Micra Transcatheter Pacing System  
Post-Approval Registry (NCT02536118) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Reference [16, 17, 22, 23] [24-26] [21] 
Study description 
Country USA, Australia, Austria, Canada, Czech 
Republic, China, Denmark, France, Greece, 
Hungary, India, Italy, Japan, Malaysia, 
Netherlands, Serbia, South Africa, Spain, 
United Kingdom 
USA, Belgium, Czech Republic, Denmark, France, 
Germany, Greece, Hungary, Iceland, Israel, Italy, 
Kuwait, Netherlands, New Zealand, Norway, 
Poland, Portugal, Russian Federation, Saudi 
Arabia, Slovenia, Spain, Sweden, Switzerland, 
United Arab Emirates, United Kingdom 
Australia, Canada, USA 
Sponsor Medtronic Medtronic St. JudeMedical 
Intervention/Product Implantation of a leadless cardiac 
pacemaker/Micra™ TPS 
Implantation of a leadless cardiac 
pacemaker/Micra™ TPS 
Implantation of a leadless cardiac 
pacemaker/Nanostim™ LCP 
Comparator NA NA NA 
Study design Single cohort safety/efficacy study  
(with historical control) 
Prospective single cohort safety/efficacy 
registry 
Single cohort safety/efficacy study 
Duration of the study November 2013 – ongoing July 2015 – ongoing February 2014 – ongoing 
Randomisation method None None None 
Blinding method (investigator, 
patient, outcomes assessor) 
Open label Open label Open label 
Intervention (n=) 630 (Efficacy cohort – 12 months) 
58 (Efficacy cohort – 24 months) 
726 (Safety cohort) 
504 (HRQoL cohort) 
Subgroup analysis – patients with elevated 
implant threshold (> 1.0 V at 0.24ms): 
83 
~ 1830 (Planned enrollment) 
701 (Efficacy cohort – 30 days) 
795 (Safety cohort – 30 days) 
~ 1567 (Planned enrollment) 
468 (HRQoL cohort) 
Control (n=) 0 0 0 
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Study (acronym, ID no.) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
The Micra Transcatheter Pacing System  
Post-Approval Registry (NCT02536118) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Population Patients indicated for VVI(R) pacing Patients indicated for VVI(R) pacing Patients indicated for VVI(R) pacing 
Inclusion criteria Class I or II indication for pacing (bradycardia 
due to atrial tachyarrhythmia, sinus node 
dysfunction, atrioventricular node 
dysfunction, or other causes) 
Patient is intended to receive or be treated 
with a Micra Transcatheter Pacing System and 
must be enrolled prior to the TPS implant 
procedure 
Chronic and/or permanent atrial fibrillation with 
2 or 3° AV or bifascicular bundle branch block 
(BBB block), including slow ventricular rates 
(with or without medication) associated with 
atrial fibrillation; or normal sinus rhythm with 
2 or 3° AV or BBB block and a low level of physical 
activity or short expected lifespan (but at least 
one year); or sinus bradycardia with infrequent 
pauses or unexplained syncope with EP findings 
Exclusion criteria Entirely pacemaker dependent (escape rhythm 
<30 bpm)* (restriction was lifted following 
review of the Early Performance Assessment) 
Existing or prior pacemaker, implantable 
cardioverter defibrillator or cardiac 
resynchronization therapy device implant; 
Unstable angina pectoris, acute myocardial 
infarction within 30d, 
Current implantation of neurostimulator or 
any other chronically implanted electronic 
device, mechanical tricuspid valve, implanted 
vena cava filter, or left ventricular assist device; 
Morbidly obese; 
Femoral venous anatomy unable for 
transcatheter procedure; 
intolerance to device material or 
hypersensitivity to <1mg dexamethasone; 
life-expectancy <12m; pregnant or 
breastfeeding women 
Patient who is, or is expected to be  
inaccessible for follow-up; 
Patient with exclusion criteria required  
by local law; 
Patient is currently enrolled in or plans to 
enroll in any concurrent drug and/or device 
study that may confound results 
Pacemaker syndrome, retrograde VA 
conduction or drop in arterial blood pressure 
with the onset of ventricular pacing; 
Pre-existing endocardial pacing or 
defibrillation leads; or 
Pre-existing pulmonary arterial hypertension or 
significant physiologically-impairing lung disease; 
Current implantation of either conventional or 
subcutaneous implantable cardioverter de-
fibrillator or cardiac resynchronization therapy; 
Mechanical tricuspid valve prosthesis; 
Implanted vena cava filter; 
Implanted leadless cardiac pacemaker; 
Evidence of thrombosis in one of the veins 
used for access during the procedure; 
Recent cardiovascular or peripheral vascular 
surgery within 30 days of enrolment 
Allergic or hypersensitive to <1mg of 
dexamethasone sodium phosphate; 
life-expectancy <12m; pregnant or 
breastfeeding women 
Primary outcome  
(including measurement tools  
and measurement times) 
S: Freedom from major complications 
related to the Micra™ TPS and/or procedures 
at 6-month post-implant (within 183 days) 
E: Adequate pacing capture threshold at  
6 months (≤ 2 V at a pulse width of 0.24 ms  
and stable (increase of ≤ 1.5 V)) 
S: Acute complication rate (within 30 days); 
S: Long-term complication free survival  
(up to 9 years) 
S: Complication-free rate 
(freedom of SADE) at 6 months 
E: Therapeutically acceptable pacing capture 
threshold (≤ 2.0 V at 0.4 msec) and a 
therapeutically acceptable sensing amplitude 
(R wave ≥ 5.0 mV, or a value equal to or 
greater than the value at implantation) 
through 6 months 
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Study (acronym, ID no.) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
The Micra Transcatheter Pacing System  
Post-Approval Registry (NCT02536118) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Secondary outcome  
(including measurement tools 
 and measurement times) 
E: Automated ventricular capture 
management feature by comparing the 
percentage of subjects with a VCM within 
+0.5 V of pacing capture thresholds 
evaluated manually at 6 months 
Rate response during treadmill testing in  
a subset of subjects 
Micra™ TPS longevity estimates at 6 months, 
electrical performance, implant procedure 
ambulatory ECG monitoring, quality of life, 
and device orientation 
S: Adverse Events  
Freedom from SADE at 12 months 
E: Pacing impedance and pacing threshold  
(up to 9 years) 
E: System longevity (up to 9 years) 
S: Complications stratified by implant type  
(up to 9 years) 
S: Micra system revision rate (including 
system explant, replacement, reposition)  
(up to 9 years) 
S: Non–device-related SAE during 6 months  
of follow-up. 
S: SADE and Non-device-related SAE during 
follow-up (Full cohort) 
Follow-up (months) Efficacy: 12 and 24 months 
Safety: 6 and 12 months 
HRQoL: 3 months 
Subgroup analysis – patients with elevated 
implant threshold (> 1.0 V at 0.24ms):  
Efficacy: 6 months 
30 days 12 weeks 
Loss to follow-up, n (%) 0 
Subgroup analysis – patients with elevated 
implant threshold (> 1.0 V at 0.24ms):  
11 (13.3) 
0 0 
Population characteristics 
Age (mean), y 75.9±10.9 (Safety cohort) 
77±11 (HRQoL cohort) 
Subgroup analysis – patients with elevated 
implant threshold (> 1.0 V at 0.24ms):  
76.0±9.0 
75.2±14.2 (Safety cohort) 75.0±12.0 
Male, n (%) 426 (58.8) (Safety cohort) 
300 (60) (HRQoL cohort) 
Subgroup analysis – patients with elevated 
implant threshold (> 1.0 V at 0.24ms):  
52 (62.7) 
495 (62.3) (Safety cohort) 292 (62.4) 
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Study (acronym, ID no.) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
The Micra Transcatheter Pacing System  
Post-Approval Registry (NCT02536118) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Pacing indication, n (%) Safety cohort: 
Bradycardia associated with persistent or 
permanent atrial tachyarrhythmia, 464 (64.0) 
Sinus node dysfunction, 127 (17.5) 
AV block, 107 (14.8) 
Other reasons, 27 (3.7) 
Bradycardia associated with persistent or 
permanent atrial tachyarrhythmia, 459 (57.7) 
AV block, 117 (14.7) 
Syncope, 112 (14.1) 
Sinus node dysfunction, 64 (8.0) 
Other reasons, 44 (5.5) 
NR8 
Comorbidities, n (%) Safety cohort: 
Diabetes, 207 (28.6) 
COPD, 90 (12.4) 
Renal dysfunction, 145 (20.0) 
CAD, 203 (28.0) 
AF, 526 (72.6) 
CHF, 123 (17.0) 
Hypertension, 570 (78.6) 
Valvular Disease, 306 (42.2) 
Subgroup analysis – patients with elevated 
implant threshold (> 1.0 V at 0.24ms): 
Diabetes, 25 (30.1) 
COPD, 6 (7.2) 
Renal dysfunction, 18 (21.7) 
CAD, 22 (26.5) 
AF, 62 (74.7) 
CHF, 14 (16.9) 
Hypertension, 63 (75.9) 
Valvular Disease, 27 (32.5) 
Diabetes, 196 (24.7) 
COPD, 67 (8.4) 
Renal dysfunction, 152 (19.1) 
CAD, 132 (16.6) 
AF, 532 (66.9) 
CHF, 46 (5.8) 
Hypertension, 454 (57.1) 
Conditions that precludes the use of  
a transvenous pacemaker, 166 (20.9) 
Previous implanted CIED, 115 (14.5) 
Diabetes, 129 (27.6) 
CAD, 176 (37.6) 
CHF, 74 (15.8) 
Hypertension, 367 (78.4) 
Valvular Disease, 58 (12.4) 
Outcomes 
Efficacy 
Adaequad Pacing performance 
(pacing threshold ≤ 1.0 V at 0.24ms) 
12 months: 586/630 (93) 
24 months: 56/58 (97) 
Subgroup analysis – patients with elevated 
implant threshold (> 1.0 V at 0.24ms): 
6 months: 51/72 (71) 
At implant: 611/701 (87.2) NR8 
                                                             
8 not reported within this publication; for efficacy and safety results see MEL-Report 2016 [1] 
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Study (acronym, ID no.) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
The Micra Transcatheter Pacing System  
Post-Approval Registry (NCT02536118) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Health related quality of life SF-36 scores [mean]; n=488 
Pysical component summary: 
pre-implant (baseline): 36.9 
3 months: 38.7 
Δ: +5% (p<0.05) 
Mental component summary: 
pre-implant (baseline): 47.8 
3 months: 51.4 
Δ: +8% (p<0.05) 
NR EuroQol EQ-5D 3L [mean utility]; n=468 
baseline: 0.739 
pre-discharge: 0.805±0.222 
week 12: 0.838±0.178; p<0.01 
Safety 
Implant success rate, n/N (%) 720/726 (99.2) 792/795 (99.6) NR8 
Overall Mortality, n/N (%) 77/745 (10.3) 22/795 (2.8) NR8 
Procedure-related mortality, n/N (%) 1/745 (0.1) 1/795 (0.1) NR8 
Cardiac mortality, n/N (%)  32/745 (4.3) NR NR8 
Cardiac morbidity, n/N (%) NR NR NR8 
Systemic infection, n/N (%) 26/726 (3.6) NR NR8 
Overall Adverse Events, n/N (%) NR NR NR8 
Serious Adverse Events, n/N (%) 226/725 (31.2)10 NR NR8 
Non-device-related SAE, n/N (%) NR NR NR8 
Overall Adverse Device Effects 
(ADE), n/N (%) 
NR NR NR8 
Serious Adverse Device Effects 
(SADE), n/N (%) 
29/726 (4.0) 12/795 (1.5) NR8 
New hospitalization, n/N (%) 17/726 (2.3) 4/795 (0.5) NR8 
Prolonged hospitalization, n/N (%) 18/726 (2.2) 9/795 (1.0) NR8 
Loss of device function, n/N (%) 2/726 (0.3) 0/795 NR8 
                                                             
  9 baseline utility obtained from a meta-analysis of single-chamber pacemaker studies in the US 
10 6 months data 
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Study (acronym, ID no.) 
Micra Transcatheter Pacing Study 
(NCT02004873) 
The Micra Transcatheter Pacing System  
Post-Approval Registry (NCT02536118) 
The LEADLESS II pacemaker IDE study 
(NCT02030418) 
Cardiac morbidity – device or 
procedure related, n/N (%) 
9/726 (1.2) 11 NR NR8 
Cardiac injury, n/N (%) 11/726 (1.5) 5/795 (0.6) NR8 
Major infections– device or 
procedure related, n/N (%) 
0/726 1/795 (0.1) NR8 
Device dislodgement, n/N (%) 0/726 1/795 (0.1) NR8 
Elevated pacing thresholds requiring 
retrieval/replacement, n/N (%) 
2/726 (0.3%) NR NR8 
ADE: Adverse device effect; AF: Atrial fibrillation; AV: Atrioventricular; BBB: Bundle branch block; CAD: Coronary artery disease; CHF: Congestive heart failure;  
COPD: Chronic obstructive pulmonary disease; E: Efficacy; ECG: Electrocardiogram; HRQoL: Health-related quality of life; LCP: Leadless cardiac pacemaker; NA: Not applicable;  
NR: Not reported; S: Safety; SADE: Serious adverse device effect; SAE: Serious adverse event; TPS: Transcatheter pacing system; VCM: Ventricular capture management;  
VVI(R): Single-chamber ventricular pacing (with response modulation) 
 
Table A-2: Leadless pacemakers: Results from observational studies (part 2) 
Study (acronym, ID no.) Da Costa 2017 Kypta 2016 Martínez-Sande 2017 Pachon 2016 
Reference [19] [20] [18] [15] 
Study description 
Country France Austria Spain Spain 
Sponsor NR NR NR NR 
Intervention/Product Implantation of a leadless 
cardiac pacemaker/Micra™ TPS 
Implantation of a leadless 
cardiac pacemaker/Micra™ TPS 
Implantation of a leadless  
cardiac pacemaker/Micra™ TPS 
Implantation of a leadless 
cardiac pacemaker/Micra™ TPS 
Comparator NA NA NA NA 
Study design Case series Case series Prospective observational study Case series 
Duration of the study May 2015 – July 2016 September 2015 – May 2016 June 2015 – May 2016 NR 
Randomisation method None None None None 
Blinding method (investigator, 
patient, outcomes assessor) 
Open label Open label Open label Open label 
                                                             
11 acute Myocardial infarction, cardiac failure or pacemaker syndrome 
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Study (acronym, ID no.) Da Costa 2017 Kypta 2016 Martínez-Sande 2017 Pachon 2016 
Intervention (n=) 14 6 30 10 
Control (n=) 0 0 0 0 
Population Patients contraindicated for or 
unable to receive conventional 
endovenous PM implantation 
Patients With Severe Device 
Infection 
Patients indicated for VVI pacing Patients indicated for VVI pacing 
Inclusion criteria Indication for pacemaker 
implantation; full or relative 
contraindications for traditional 
transvenous PM implantation 
Pacemaker dependance; lead 
extraction due to severe device 
infection (class I indication) 
Indication for single-chamber 
pacemaker placement; age ≥ 65 
years; 
Standard indication for a 
permanent pacemaker; clinical 
profile and indication for  
VVI pacing 
Exclusion criteria NR NR NR Patients without own cardiac 
rhythm 
Primary outcome  
(including measurement tools 
and measurement times) 
Implant success rate; pacing 
performance 
Ongoing infection (C-reactive 
protein, white blood count) 
Electrical parameters at  
implantation and over follow-up 
NR 
Secondary outcome (including 
measurement tools and 
measurement times) 
Absence of serious adverse 
events at 3 months 
Ongoing infection or reinfection 
(PET scan); 
Major or minor complications 
Complications related to the 
implantation procedure 
NR 
Follow-up (months) 3 months 3 months 1, 3, 6 and 12 months 
(mean 5.3±3.3) 
mean 55±33 days 
Loss to follow-up, n (%) 0 0 NR 0 
Population characteristics 
Age (mean), y 75.0±10.0 78.3±11.9 79.4±6.4 77.1±5.1 
Male, n (%) 7 (50) 5 (83.3) 20 (66.7) 6 (60) 
Pacing indication, n (%) AV block, 10 (71.4) 
Uncontrolled AF, 3 (21.4) 
Bradyarrhythmia, 1 (7.1) 
AV block, 6 (100) Slow AF, 28 (93.3) 
Trifascicular block and syncope, 1 (3.3) 
Recurrent episodes of rapid atrial 
tachycardia, 1 (3.3) 
Permanent AF, 7 (70) 
Bradycardia-tachycardia 
syndrome, 2 (20) 
AV block, 1 (10) 
Comorbidities, n (%) Diabetes, 6 (42.8) 
COPD, 2 (14.3) 
Renal dysfunction, 9 (64.3) 
CAD, 3 (21.4) 
AF, 9 (64.3) 
CHF, 8 (57.1) 
Hypertension, 12 (85.7) 
Valvular Disease, 3 (21.4) 
NR Diabetes, 11 (36.6) 
COPD, 60 (20.0) 
Renal dysfunction, 2 (6.6) 
Peripheral arterial disease, 5 (16.6) 
AF, 28 (93.3) 
IHD, 6 (20.0) 
Hypertension, 25 (83.3) 
Valvular Disease, 8 (26.6) 
Diabetes, 2 (20) 
COPD, 1 (10) 
Renal dysfunction, 2 (20) 
Hypertension, 8 (80) 
Dyslipidemia, 4 (40) 
Obstructive sleep apnea, 1 (10) 
AF, 8 (80) 
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Study (acronym, ID no.) Da Costa 2017 Kypta 2016 Martínez-Sande 2017 Pachon 2016 
Outcomes 
Efficacy 
Adaequad Pacing performance 
(pacing threshold ≤ 1.0 V at 0.24ms) 
14/14 (100) 6/6 (100) 6 months: 16/16 (100) 
12 months: 4/4 (100) 
10/10 (100) 
Health-related quality of life NR NR NR NR 
Safety 
Implant success rate, n/N (%) 14/14 (100) 6/6 (100) 30/30 (100) 10/10 (100) 
Overall Mortality, n/N (%) 0/14 0/6 NR 0/10 
Procedure-related mortality, n/N (%) 0/14 0/6 NR 0/10 
Cardiac mortality, n/N (%)  0/14 0/6 NR 0/10 
Cardiac morbidity, n/N (%) 1/14 (7.1) NR NR NR 
Systemic infection, n/N (%) NR 0/6 0/30 NR 
Overall Adverse Events, n/N (%) NR NR NR NR 
Serious Adverse Events, n/N (%) NR NR NR NR 
Non-device-related SAE, n/N (%) NR NR NR NR 
Overall Adverse Device Effects 
(ADE), n/N (%) 
1/14 (7.1) NR NR 0/10 
Serious Adverse Device Effects 
(SADE), n/N (%) 
NR NR NR 0/10 
New hospitalization, n/N (%) NR NR NR NR 
Prolonged hospitalization, n/N (%) NR NR NR NR 
Loss of device function, n/N (%) 0/14 NR NR NR 
Cardiac morbidity – device or 
procedure related, n/N (%) 
1/14 (7.1) NR 1/30 (3.3) 0/10 
Cardiac injury, n/N (%) NR NR NR NR 
Major infections– device or 
procedure related, n/N (%) 
NR 0/6 NR 0/10 
Device dislodgement, n/N (%) 0/14 0/6 0/30 0/10 
Elevated pacing thresholds requiring 
retrieval/replacement, n/N (%) 
0/14 0/6 0/30 0/10 
ADE: Adverse device effect; AF: Atrial fibrillation; CAD: Coronary artery disease; CHF: Congestive heart failure; COPD: Chronic obstructive pulmonary disease; IHD: Ischemic heart disease; NA: Not applicable; NR: 
Not reported; SADE: Serious adverse device effect; VVI(R): Single-chamber ventricular pacing (with response modulation) 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA [37] 
and in the Guidelines of EUnetHTA [38, 39].  
Table A-3: Risk of bias – study level (case series), see [27] 
Study 
Micra 
Transcatheter 
Pacing Study  
(NCT02004873) 
The Micra Transcatheter 
Pacing System  
Post-Approval Registry 
(NCT02536118) 
The LEADLESS II 
pacemaker IDE study 
(NCT02030418) Da Costa 2017 Kypta 2016 
Martínez-
Sande 2017 Pachon 2016 
reference/ID [16, 17, 22, 23] [24-26] [21] [19] [20] [18] [15] 
Study objective 
1. Is the hypothesis/aim/objective of 
the study stated clearly in the abstract, 
introduction, or methods section? 
Yes Yes Yes Yes Unclear Yes Unclear 
Study population 
2. Are the characteristics of the 
participants included  
in the study described? 
Yes Yes Yes Yes Yes Yes Yes 
3. Were the cases collected in more 
than one centre? 
Yes Yes Yes No No No No 
4. Are the eligibility criteria (inclusion 
and exclusion criteria) for entry into 
the study explicit and appropriate? 
Yes Yes Yes Partially Partially Partially Partially 
5. Were participants recruited 
consecutively? 
Unclear Unclear Yes Yes Unclear Yes Unclear 
6. Did participants enter the study at 
similar point in the disease? 
No No No No Yes No No 
Intervention and co-intervention 
7. Was the intervention clearly 
described in the study? 
Yes Yes Yes Yes Yes Yes Yes 
8. Were additional interventions  
(co-interventions) clearly reported  
in the study? 
No No No No Partially No No 
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Study 
Micra 
Transcatheter 
Pacing Study  
(NCT02004873) 
The Micra Transcatheter 
Pacing System  
Post-Approval Registry 
(NCT02536118) 
The LEADLESS II 
pacemaker IDE study 
(NCT02030418) Da Costa 2017 Kypta 2016 
Martínez-
Sande 2017 Pachon 2016 
Outcome measures 
9. Are the outcome measures clearly 
defined in the introduction or methods 
section? 
Yes Yes Yes Yes Partially Partially No 
10. Were relevant outcomes 
appropriately measured with objective 
and/or subjective methods? 
Yes Yes Yes Yes Yes Yes Unclear 
11. Were outcomes measured before 
and after intervention? 
No No No No No No No 
Statistical Analysis 
12. Were the statistical tests used  
to assess the relevant outcomes 
appropriate? 
Yes Yes Yes Unclear Unclear Yes Unclear 
Results and Conclusions 
13. Was the length of follow-up reported? Yes Yes Yes Yes Yes Yes Yes 
14. Was the loss to follow-up reported? Yes Yes Yes No No No Yes 
15. Does the study provide estimates  
of the random variability in the data 
analysis of relevant outcomes? 
Yes Yes Yes Yes Yes Yes Yes 
16. Are adverse events reported? Yes Yes Yes Partially Partially Partially Partially 
17. Are the conclusions of the study 
supported by results? 
Yes Yes Yes No Yes Yes Yes 
Competing interest and source of support 
18. Are both competing interest and 
source of support for the study reported? 
Yes Yes Yes Partially Partially Partially Partially 
Overall Risk of bias Low Low Low High High High High 
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Applicability table 
Table A-4: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The majority of study participants had chronic atrial fibrillation with AV block. A substantial number of participants had a pacemaker indication due to SND 
or AV block without AF based on individual factors precluding dual-chamber pacing. It is unclear if the selection of patients for VVI pacing in Austria results 
in comparable frequencies of the respective indication groups. 
Intervention In the studies, the intervention was the transcatheter implantation of one of two marketed products (Nanostim™ LCP and Micra™ TPS), which corresponds 
to the products likely to be used in Austria. 
Comparators There were no comparators. 
Outcomes The main outcomes reported in the studies were pacing performance for efficacy and complication rates for safety. Health-related quality of life was the 
only clinically relevant efficacy outcome reported in the studies. For safety, the reported outcomes are clinically relevant. 
Setting In all studies, the intervention was performed in a clinical setting, corresponding to the utilisation setting in Austria. Four studies were led in Europe,  
one in Australia, Canada and the US and two were global studies with study centres in North America, Europe, Africa, Asia and Australia. 
No applicability issues are expected from the geographical setting.  
 
 
List of ongoing randomised controlled trials 
Table A-5: List of ongoing non-RCT studies on leadless pacemakers 
Identifier/Trial name Patient population Intervention Comparison Primary Outcome 
Primary  
completion date Sponsor 
NCT02030418  
The LEADLESS Pacemaker  
IDE Study (Leadless II) 
Bradycardia Device: Leadless 
Pacemaker 
None Complication-Free Rate 
Pacing thresholds and  
R-wave amplitudes within 
the therapeutic range 
September 2017 St. Jude 
Medical 
NCT02536118  
Micra Transcatheter Pacing 
System Post-Approval Registry 
Bradycardia Device: Micra™ 
Transcatheter Pacing 
System 
None Acute complication rate 
Long-term complication 
free survival 
August 2026 Medtronic 
NCT02004873  
Micra Transcatheter  
Pacing Study 
Class I or II Indication for 
Implantation of a Single Chamber 
Ventricular Pacemaker According 
to ACC/AHA/HRS 2001 Guidelines 
and Any National Guidelines 
Device: Micra™ 
Pacemaker Implant 
None Major Complications 
Pacing Capture Threshold 
Estimated Study 
Completion Date: 
May 2017 
Primary Completion 
Date: May 2015 
Medtronic 
Cardiac 
Rhythm and 
Heart 
Failure 
NCT02051972  
The LEADLESS Observational 
Study 
Indications for  
VVI(R) Pacemaker 
Device: Implanted with a 
Nanostim™ leadless 
pacemaker system 
None Complication free-rate June 2017 St. Jude 
Medical 
NCT03039712 
Longitudinal Coverage With 
Evidence Development Study 
on Micra Leadless Pacemakers 
(Micra CED) 
Bradycardia Device: Micra™ leadless 
pacemaker therapy 
Single Chamber 
Transvenous 
pacemaker 
Acute complication rate 
The 2-year survival rate of 
patients implanted with a 
Micra leadless pacemaker 
June 2021 Medtronic 
Leadless pacemakers for right ventricle pacing 
50 LBI-HTA | 2017 
Literature search strategies 
Search strategy for CRD 
Search Name: Leadless Pacemakers_Update 2017 (TS) 
Search Date: 06.04.2017 
ID Search 
#1 MeSH DESCRIPTOR Pacemaker, Artificial EXPLODE ALL TREES 
#2 MeSH DESCRIPTOR Cardiac Pacing, Artificial EXPLODE ALL TREES 
#3 (pacemaker*) 
#4 #1 OR #2 OR #3 
#5 (leadless) 
#6 ((leadless OR transcatheter*) NEAR pacing) 
#7 #5 OR #6 
#8 #4 AND #7 
#9 * WHERE LPD FROM 09/12/2015 TO 06/04/2017 
#10 #8 AND #9 
Total: 1 Hit 
 
Search strategy for Embase 
Search Name: Leadless Pacemakers_Update 2017 (TS) 
Search Date: 06.04.2017 
ID Search 
#1 'heart pacing'/exp 
#2 'artificial heart pacemaker'/exp 
#3 pacemaker* 
#4 peacemaker* 
#5 'pace-maker' 
#6 'pace-makers' 
#7 'peace-maker' 
#8 'peace-makers' 
#9 ‘heart pacing’/exp OR ‘artificial heart  pacemaker’/exp OR pacemaker* OR peacemaker* OR ‘pace-maker’ 
OR ‘pace-makers’ OR ‘peace-maker’ OR ‘peace-makers’ 
#10 leadless 
#11 (leadless OR transcatheter*) NEAR/4 pacing 
#12 leadless OR (leadless OR transcatheter*) NEAR/4 pacing 
#13 ‘heart pacing’/exp OR ‘artificial pacemaker’/exp OR pacemaker* OR peacemaker* OR ‘pace-maker’ OR 
‘pace-makers’ OR ‘peace-maker’ OR ‘peace-makers’ AND (leadless OR (leadless OR transcatheter*)  
NEAR/4 pacing) 
#14 'heart pacing'/exp OR 'artificial heart pacemaker'/exp OR pacemaker* OR peacemaker* OR pace-maker' OR 
'pace-makers' OR 'peace-maker' OR 'peace-makers' AND (leadless OR (leadless OR transcatheter*)  
NEAR/4 pacing) AND [9-12-2015]/sd 
Total: 144 Hits 
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Search strategy for Medline 
Search Name: Leadless Pacemakers_Update 2017 (TS) 
Search Date: 06.04.2017 
ID Search 
#1 exp Pacemaker, Artificial/ 
#2 exp Cardiac Pacing, Artificial/ 
#3 pacemaker*.mp. 
#4 1 or 2 or 3 
#5 leadless.mp. 
#6 ((leadless or transcatheter*) adj5 pacing).mp. 
#7 5 or 6 
#8 4 and 7 
#9 (“26227982” or “26321198” or “25546862” or “25906000” or “24732365” or “25319956” or “25223835” or 
“25040838” or “25606637” or “25881931” or “25881930“ or “25289391” or “24798955” or “24497573” or “24664277” 
or “24519117” or “22581741” or “23168008” or “23703364” or “23620339” or “23687235” or “23104398” or 
“23027843” or “22138425” or “22427074” or “21798878” or “21276495” or “21391322” or “21135811” or “20553288” or 
“20927783” or “20465717” or “20136603” or “19467502” or “19427274” or “19170906” or “16810701” or “12001828” 
or “10505390” or “3520168” or “26370553” or “26337997” or “26024918” or “26183288” or “26102353” or “26370476” 
or “26487626” or “26045305” or “26282468” or “26427291” or “26233700” or “26261157” or “25639949” or 
“25123732” or “25855677” or “25814425” or “25367066” or “25610802” or “26606963” or “26551877” or “26551666” 
or “26539965” or “26519678” or “26458791” or “26261298” or “26100053” or “21261667” or “24347317” or 
“23449923” or “21699827” or “22968177” or “21195583” or “26307459” or “24056152” or “15478788”).ui. 
#10 8 not 9 
#11 remove duplicates from 10 
Total: 91 Hits 
 
Search strategy for Pubmed 
Search Name: MEL 2016: Leadless Pacemakers: Update 2017(ST) 
Search Date: 06.04.2017 
ID Search 
#1 (((Pacemaker, Artificial[MH] OR Cardiac Pacing, Artificial[MH] OR pacemaker*) AND (leadless OR 
leadless pac* OR transcatheter pac*))) AND (“2015/12/09”[Date – Entrez] : “3000”[Date – Entrez]) 
(((Pacemaker, Artificial[MH] OR Cardiac Pacing, Artificial[MH] OR pacemaker*) AND (leadless OR 
leadless pac* OR transcatheter pac*))) AND ("2015/12/09"[Date – Entrez] : “3000”[Date – Entrez]) 
Total: 77 Hits 
 
Search strategy for Cochrane 
Search Name: Leadless Pacemakers (Update 2017) 
Search Date: 04.04.2017 
ID Search 
#1 MeSH descriptor: [Pacemaker, Artificial] explode all trees 
#2 MeSH descriptor: [Cardiac Pacing, Artificial] explode all trees 
#3 pacemaker* (Word variations have been searched) 
#4 #1 or #2 or #3 
#5 (leadless or transcatheter*) near pacing (Word variations have been searched) 
#6 leadless (Word variations have been searched) 
#7 #5 or #6 
#8 #4 and #7 Publication Year from 2015 to 2017 
Total: 9 Hits 
  
 
